MRS
1885
patientsinclass1havenoneofthecharacteristics,patientsinclass2haveoneortwoofthecharacteristicsandpatientsinclass3haveallthreecharacteristics.WhenHSCTisattempted,thepatientsarethenassignedtooneoftwoconditioningregimensonthebasisoftheirPesaroriskclassification.Theconditioningregimenusescytotoxicagentstosuppressbonemarrowactivityandimmunitybeforehematopoieticstemcellinfusion,therebyhelpingtominimizehematopoieticstemcellrejection.Low-riskpatientswithPesaroclass1orclass2diseasehaveexcellenttogoodresultsafterHSCT,whilepatientswithclass3diseasehavepoorresultsmainlyfromahighrejectionrateduetoattenuatedconditioning[6].Forclass1,class2andclass3patients,theprobabilityofsurvivalandevent-freesurvivalare95%and90%,86%and82%,and87%and63%,respectively[7].Newerpreparatoryregimenshavesubstantiallyimprovedthesurvivalrateto93%withtherejectionratefallingfrom30%to8%inpatientswithclass3diseaseyoungerthan17yearsofage[8].WhilethePesaroclassificationisuseful,ithasinherentlimitations.Forexample,hepatomegalyissubjectivelydefinedasaliveredgepalpable2cmormorebelowthecostalmargin,whilehistologicalevaluationofportalfibrosisisnecessarilyinvasive.Thissaid,todate,abetterpre-transplantationriskstratificationassessmentisnotavailable[9].
MRimagingcanaccuratelydemonstratered/yellowbonemarrowdistributionandconversionpatterns[10,11].ItcanrevealabnormalappearanceswithprolongedT1marrowvaluesbeingusedtoshowimprovementaftertreatmentinhematologicalmalignancies,suchasleukemia,myelomaandlymphoma[12,13].However,afewstudieshavespecificallyaddressedtheMRbonemarrowimaginginthalassaemia[14,15].Theradiographicfeaturesofbeta-thalassemiaaredueinlargeparttomarrowhyperplasiainresponsetochronicanemia[14].OnMRimaging,redmarrowproliferationwasrevealedaspersistenceorreconversionofredmarrowareasandmaybepresentdespitehypertransfusiontherapy.Ontheotherhand,repeatedtransfusiontherapyandexcessivegastrointestinalabsorptionofironleadtohemosiderosis,whichmayoccurinactiveredmarrowregionsdespitechelationtherapyandresultinsubstantiallyreducedbonemarrowMRsignalduetomagneticsusceptibilityeffectsandassociatedT2shortening[15].However,bonemarrowMRchangesafterHSCThadnotbeendescribedinpatientswiththalassemiayet.Inparticular,thebenefitofMRimagingassessmentofbonemarrowinpatientspriortoHSCThasneverbeenspecificallyaddressed.ItisunknownwhetherMRimagingispredictiveofpatientoutcomefollowingHSCTforbeta-thalassemiamajor.
Inthisstudy,MRassessmentofthemarrowintheproximalfemurwascorrelatedwithclinicaloutcomefollowingHSCTinbeta-thalassemiamajorpatientstodeterminewhetherMRappearanceswerepredictiveofsuccessfuloutcome.
Materialsandmethods
Patients
BetweenMay1998andMay2007,prospectivefemoralmarrowMRimagingexaminationwereperformedin27childrenwithbeta-thalassemiamajorpreparedforalloge-neicHSCT.ThestudyprotocolincludingMRexaminationwasapprovedbytheHumanResearchCommitteeofourinstitution.Informedconsentwasobtainedfromtheparentsofallparticipatingpatientsfollowingdetailedexplanation.Therewere12boysand15girls(meanageatthetimeofHSCT:6years7months,range:2–13years).Thediagnosisofbeta-thalassemiamajorwasmadebyhemoglobinelectrophoresisorgenotypicalanalysisinallpatients.Meandurationofsymptomsofthalassemiawas5years3months(range:1–11years).Eighteenpatientshadbeentreatedwithanadequatebloodtransfusionregime(i.e.,hemoglobinlevelmaintainedat90–120g/l),whileninepatientsreceivedaninadequatetransfusionregime(hemoglobinlevelmaintainedat60–90g/l).Eightpatientshadbeenchelatedadequatelywithdeferoxamine,i.e.,deferoxaminetherapyinitiatedwithin18monthsoffirsttransfusionandadministeredsubcutaneouslyfor10hcontinuouslyfor5dayseachweek.Thirteenpatientswerechelatedinadequatelywithdeferoxamine,whiletheremainingsixpatientsdidnotreceivechelation.Threepatientshadpreviouslyundergonesplenectomy.Measure-mentofserumferritinandliverbiopsywasperformedinallpatientswithin7daysofMRimaging.BiopsymaterialwasstainedwithPrussianbluetoevaluatehemosiderosisandstainedusingthemethodofMassontrichromestaining[16]toevaluateportalfibrosis.HSCT
BeforeHSCT,14(52%)and13(48%)ofthe27patientswereclassifiedasclass2andclass3atthetimeofHSCTaccordingtoPesaroriskclassification,respectively[1].Theconditioningregimenin12patientsconsistedofbusulphan(14mg/kgondays 9to 6)andcyclophos-phamide(200mg/kgondays 5to 2).Fifteenpatientsreceivedeitheradecreaseddoseofcyclophosphamide(150mg/kg;tenpatients)oranincreaseddoseofbusulphan(16mg/kg;fivepatients).Additionalimmunosuppressiveagentswereaddedtotheconditioningregimentolessengraftrejection.Theseincludedantithymocyteglobulinglobulin(30mg/kg/day)orantilymphocyticglobulin(12.5mg/kg/day)for3–5daysinallpatientsandfludarabine(25mg/m2/day)for2–5daysin12patients.Oneclass2patientandoneclass3patientdiedwhilereceivingtheconditioningregimen,onefromheartfailure,theotherfromhepaticveno-occlusivedisease.Theremaining25patientsunderwentHSCT.Detailsofrelevantpre-HSCTfeaturesaregiveninTable1.Ofthe25patientsundergoingHSCT,17patientsreceivedumbilicalcord
with high MW and then to decrease the load in next step 30 Methods to Improve Electrochemical Treatment Effect of Dye Wastewater ZM Shen*, D Wu, J....
Science, 2008, 319, 1229—1232 苯乙烯-丙稀酰胺共聚物功能化石墨烯: Shen J F, Hu Y Z, Li C, Qin C, Ye M X. Synthesis of amphiphilic graphene ...
Strueturalhealthmonitoring,2008(2):91,102. [18] Shen,J. , Cheng , K.E.,Cho,Y.Hiltz.S.R. and Bieber,M.(2000) Evaluation of an Online ...
苏木降糖活性成分研究〔 2008. 院药物研究所, Shen J, Zhang H, Lin H Y, et al. Brazilein protects the brain against focal cerebral ischemia reperfusion ...
(up to Dec. 13, 2008) Table 1 The most highly cited articles in JZUS-A from 2000 to 2008 (up to Dec. 13, 2008) Citations 16 Author SHEN J ...
2008 宏基因组学 (M etageno ics)的研究现状和发展趋势 [ J]. 环境科学学报, 28( 2 ): 209- 218 . m H e J Z Zhang L M, Shen J P, et al....
Sci. Eng., 2008, 21: 97-100 ( ? , ??. ? ??? ??? ?? [J]. ?? ? ? , 2008, 21: 97-100) [9] Li L F, Shen J N, Li M C, et...
J. Bacteriol. 190:3006-17. 8. Zhang S, Wei W., Hou. G, Zhang C, Liang P., Ni J., Sheng D., Shen Y. (2008) Archaeal DNA helicase HerA...
(2) 19.Hao R.Qian W.Zhang L H Aqueous dispersions of TCNQ-anion-stabilized graphene sheets 2008(48) 20.Shen J F.Hu Y Z.Li C Layer-by-layer ...
热门文档